Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,650 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.
Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA; VITALITY-ALS Study Group. Shefner JM, et al. Among authors: meng l. Amyotroph Lateral Scler Frontotemporal Degener. 2019;0(0):1-11. doi: 10.1080/21678421.2019.1612922. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31081694 Clinical Trial.
A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis.
Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI; Tirasemtiv in Myasthenia Gravis Study Group. Sanders DB, et al. Among authors: meng l. Neurotherapeutics. 2015 Apr;12(2):455-60. doi: 10.1007/s13311-015-0345-y. Neurotherapeutics. 2015. PMID: 25742919 Free PMC article. Clinical Trial.
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.
Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews JA; BENEFIT-ALS Study Group. Shefner JM, et al. Among authors: meng l. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):426-435. doi: 10.3109/21678421.2016.1148169. Epub 2016 Mar 16. Amyotroph Lateral Scler Frontotemporal Degener. 2016. PMID: 26982815 Clinical Trial.
CK-2127107 amplifies skeletal muscle response to nerve activation in humans.
Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. Andrews JA, et al. Among authors: meng l. Muscle Nerve. 2018 May;57(5):729-734. doi: 10.1002/mus.26017. Epub 2017 Dec 11. Muscle Nerve. 2018. PMID: 29150952 Free PMC article. Clinical Trial.
Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis.
Jahandideh S, Taylor AA, Beaulieu D, Keymer M, Meng L, Bian A, Atassi N, Andrews J, Ennist DL. Jahandideh S, et al. Among authors: meng l. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):294-302. doi: 10.1080/21678421.2017.1418003. Epub 2017 Dec 20. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29260584
6,650 results